Sign In
×Jamjoom Pharma shareholders approve 15% dividend for H2 2023Argaam05/06/2024
Tadawul: Bahri, Jamjoom Pharma go ex-dividend todayArgaam Special04/06/2024
United Securities sets rating, TP for Jamjoom PharmaArgaam19/05/2024
United Securities sets rating, TP for Jamjoom PharmaArgaam19/05/2024
GIB Capital previews Q1 2024 earningsArgaam14/04/2024
Senior execs of Aramco, SNB, eXtra, stc highest paid in 2023Argaam Special21/04/2024
Highest-paid executives, board members of Saudi-listed firms in 2023Argaam Special16/04/2024
Jamjoom Pharma seen to post profit growth in Q4 2023Argaam Special20/02/2024
How did analysts view TASI performance, top picks for 2024?Argaam Special09/01/2024
How did analysts view Jamjoom Pharma’s Q3 financials?Argaam Special05/12/2023
Market Data
Last Trade | 141.00 |
Change | 0.40 |
Change (%) | 0.28 |
Open | 139.00 |
Low | 138.00 |
High | 141.00 |
Prev. Close | 140.60 |
Change (3M) | 1.59 % |
Change (6M) | 30.31 % |
Volume | 97,804 |
Turnover | 13,641,286.00 |
Transactions | 1,120 |
Market Value | 9,870.00 |
Avg. Volume (3M) | 231,246.58 |
Avg. Turnover (3M) | 31,345,603.22 |
Avg. Transaction (3M) | 2,158.00 |
Change(12M) | n/a |
YTD | 22.61 % |
Event Date
|
Event
|
Venue
|
|
---|---|---|---|
04-07-2024
|
General Assembly | - | |
13-06-2024
|
Cash Dividend Distribution | - | |
04-06-2024
|
General Assembly | - | |
04-06-2024
|
Ex-dividend Date | - | |
25-03-2024
|
Conferences | - | |
more |
Date | Research firm | Rating |
|
United Securities Company | Buy |
|
United Securities Company | Hold |
|
GIB Capital | Neutral |
|
Al Rajhi Capital | Overweight |
Call Request